ARS Pharmaceuticals, Inc. $SPRY Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 94.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,362 shares of the company’s stock after selling 176,364 shares during the quarter. Pictet Asset Management Holding SA’s holdings in ARS Pharmaceuticals were worth $121,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in SPRY. CWM LLC grew its stake in ARS Pharmaceuticals by 243.7% in the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock valued at $26,000 after acquiring an additional 1,806 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after acquiring an additional 982 shares during the period. Russell Investments Group Ltd. grew its stake in ARS Pharmaceuticals by 197.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after acquiring an additional 4,427 shares during the period. Quantbot Technologies LP acquired a new stake in ARS Pharmaceuticals in the 3rd quarter valued at $82,000. Finally, Osaic Holdings Inc. grew its stake in ARS Pharmaceuticals by 52.8% in the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after acquiring an additional 1,803 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Trading Down 1.6%

Shares of SPRY stock opened at $8.60 on Tuesday. The stock’s fifty day moving average is $8.39 and its two-hundred day moving average is $9.33. The company has a debt-to-equity ratio of 1.47, a quick ratio of 7.06 and a current ratio of 7.28. The firm has a market capitalization of $853.98 million, a P/E ratio of -4.91 and a beta of 0.93. ARS Pharmaceuticals, Inc. has a fifty-two week low of $6.66 and a fifty-two week high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.42). The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $25.58 million. ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%. Research analysts expect that ARS Pharmaceuticals, Inc. will post -1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on SPRY shares. Leerink Partners set a $26.00 price objective on ARS Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, March 10th. Northland Securities started coverage on ARS Pharmaceuticals in a report on Thursday, April 9th. They issued an “outperform” rating and a $25.00 price objective on the stock. Zacks Research upgraded ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings lowered ARS Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ARS Pharmaceuticals has an average rating of “Hold” and an average price target of $28.25.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.